共 231 条
[31]
Hammond J(1999)Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6 J Immunol (Baltimore, Md: 1950) 162 1200-275
[32]
Leister-Tebbe H(2002)New evidence for transmitter role of VIP in the airways: impaired relaxation by a catalytic antibody Pulm Pharmacol Ther 15 121-2551
[33]
Gardner A(2007)Role of c-fos gene in vasoactive intestinal peptide promoted synthesis of pulmonary surfactant phospholipids Regul Pept 140 117-876
[34]
Abreu P(2010)Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis Am J Respir Crit Care Med 182 540-2574
[35]
Bao W(2015)Vasoactive intestinal peptide suppresses macrophage-mediated inflammation by downregulating interleukin-17A expression via PKA- and PKC-dependent pathways Int J Exp Pathol 96 269-1346
[36]
Wisemandle W(2010)Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels Mol Cell Biol 30 2537-1294
[37]
Jayk Bernal A(2006)Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis Arthritis Rheum 54 864-8125
[38]
Gomes da Silva MM(2020)Vasoactive intestinal peptide in checkpoint inhibitor-induced pneumonitis N Engl J Med 382 2573-1937
[39]
Musungaie DB(2003)Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension J Clin Invest 111 1339-470
[40]
Kovalchuk E(2008)Inhalation of vasoactive intestinal peptide in pulmonary hypertension Eur Respir J 32 1289-943